Photo from wikipedia
Since the outbreak of COVID-19 in December 2019, more than 4 million people have died worldwide. The global pandemic of COVID-19 has prompted each country to issue an emergency use… Click to show full abstract
Since the outbreak of COVID-19 in December 2019, more than 4 million people have died worldwide. The global pandemic of COVID-19 has prompted each country to issue an emergency use authorization for COVID-19 vaccines. In South Korea, the Ministry of Food and Drug Safety authorized the administration of four vaccines; Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273), Oxford-AstraZeneca (ChAdOx1), and Johnson & Johnson's Janssen (JNJ-78436735). Although these vaccines were presumed to be safe, several nonspecific skin eruptions have been reported after the health system initiated public COVID-19 vaccination1 . Here, we report a patient who developed de novo erythema multiforme (EM) following COVID-19 vaccination with BNT162b2.
Journal Title: Journal of the European Academy of Dermatology and Venereology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!